Abstract
Administration of L-DOPA to rats treated as neonates or as adults with 6-hydroxydopamine (6-OHDA; Breese and Traylor, 1970; Smith et al., 1973) results in enhanced behavioral responses (Breese, 1975). However, behavioral responses to L-DOPA differ depending on the age at which dopaminergic fibers are destroyed (Breese et al., 1984). For example, following L-DOPA, rats lesioned with 6-OHDA as neonates show self-biting and self-mutilation behavior, but rats treated as adults do not (Breese et al., 1984). In initial experiments, Breese et al. (1984) observed that cis flupentixol was more potent than haloperidol in antagonizing self-biting induced by L-DOPA in neonatally lesioned rats, suggesting that D1-dopamine (DA) receptors were involved in the behavioral supersensitivity observed in rats whose DA-containing neurons were destroyed during development (Breese et al., 1984). The availability of agonists and antagonists with specificity for D1-and D2-DA receptors and animal models by which to study D1-and D2-DA receptor responses allowed us to test this hypothesis as well as to evaluate further the neurobiology of these receptor subtypes (Breese et al., 1985ab, 1986, 1987).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Breese, G.R. (1975). Chemical and immunochemical lesions by specific neurotoxic substances and antisera. Handbook of Psychopharmacology, 1, 137–189.
Breese, G.R., Baumeister, A.A., McCown, T.J., Emerick, S.G., Prye, G.D., Crotty, K. and Mueller, R.A. (1984). Behavioral differences between neonatal and adult 6-hydroxydoparainetreated rats to dopamine agonists: Relevance to neurological symptoms in clinical syndromes with reduced brain dopamine. J. Pharmacol. Exp. Ther., 231, 343–354.
Breese, G.R., Baumeister, A., Napier, T.C., Prye, G.D. and Mueller, R. A. (1985a). Evidence that D-1 dopamine receptors contribute to the supersensitive behavioral responses induced by L-dihydroxyphenylalanine in rats treated neonatally with 6-hydroxydopamine. J. Pharmacol. Exp. Ther., 234, 287–295.
Breese, G.R., Duncan, G.E., Napier, T.C., Bondy, S.C., Iorio, L.C. and Mueller, R.A. (1987). 6-Hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1 and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding. J. Pharmacol. Exp. Ther., 240, 167–176.
Breese, G.R., Mueller, R.A., Napier, T.C. and Duncan, G.E. (1986). Neurobiology of D1 dopamine receptors after neonatal-6-OHDA treatment: Relevance to Lesch-Nyhan disease. Adv. Exp. Med. Biol., 204, 197–215.
Breese, G.R., Napier, T.C. and Mueller, R.A. (1985b). Dopamine agonist-induced locomotor activity in rats treated with 6-hydroxydopamine at differing ages: Functional supersensitivity of D-1 dopamine receptors in neonatally lesioned rats. J. Pharmacol. Exp. Ther., 234, 447–455.
Breese, G.R. and Traylor, T.D. (1970). Effects of 6-hydroxydopamine on brain norepinephrine and dopamine: Evidence for selective degeneration of catecholamine neurons. J. Pharmacol. Exp. Ther., 174, 413–420.
Bruno, J.P., Stricker, E.M. and Zigmond, M.J. (1985); Rats given dopamine-depleting brain lesions as neonates are subsensitive to dopaminergic antagonists as adults. Behav. Neurosci. 99, 771–775.
Creese, I., Burt, D.R. and Snyder, S.H. (1977). Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity. Science 197, 596–598.
Creese, I. and Chen, A. (1985). Selective D1 dopamine receptor increase following chronic treatment with SCH-23390. Eur. J. Pharmacol. 109, 127–128.
Criswell, H.E., Mueller, R.A. and Breese. G.R. (1987). Sensitization following repeated administration of the direct acting D1-dopamine agonist SKF-38393 in neonatally but not adult-6-OHDA lesioned rats. Soc. Neurosci. Abst.
Duncan, G., Criswell, H., McCown, T.J., Paul, I., Mueller, R.A. and Breese, G.R. (1987). Behavioral and neurochemical responses to haloperidol and SCH-23390 in rats treated neonatally or as adults with 6-hydroxydopamine. J. Pharmacol. Exp. Ther. In Press.
Iorio, L.C., Barnett, A., Billard, W. and Gold, E.H. (1986). Benzazepines: Structure-activity relationships between D1 receptor blockade and selected pharmacological effects. Adv. Exp. Med. Biol. 204, 1–14.
Lloyd, K.G., Hornykiewicz, O., Davidson, L., Shannak, K., Farley, I., Goldstein, M., Shibuya, M., Kelley, W.N. and Fox, I.H. (1981). Biochemical evidence of dysfunction of brain neurotransmitters in the Lesch-Nyhan syndrome. N. Eng. J. Med., 305, 1106–1111.
MacKenzie, R.G. and Zigmond, M.J. (1985). Chronic neuroleptic treatment increases D2 but not D1 receptors in rat striatum. Eur. J. Pharmacol. 113, 159–165.
Smith, R.D., Cooper, B.R. and Breese, G.R. (1973). Growth and behavioral changes in developing rats treated intraci8ternally with 6-hydroxydopamine: Evidence for involvement of brain dopamine. J. Pharmacol. Exp. Ther., 185, 609–619.
Walters, J.R., Bergstrom, D.A., Carlson, J.H., Chase, T.N., and Braun, A.R. (1987). D1 dopamine receptor activation required for postsynaptic expression of D2 agonist effects. Science 236, 719–722.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Copyright information
© 1988 George R. Breese, Hugh E. Criswell, Gary E. Duncan, Thomas J. McCown and Robert A. Mueller
About this chapter
Cite this chapter
Breese, G.R., Criswell, H.E., Duncan, G.E., McCown, T.J., Mueller, R.A. (1988). Neurobiology of Supersensitive D1 and D2-Dopamine Receptors after 6-Hydroxydopamine Lesions. In: Beart, P.M., Woodruff, G.N., Jackson, D.M. (eds) Pharmacology and Functional Regulation of Dopaminergic Neurons. Satellite Symposia of the IUPHAR 10th International Congress of Pharmacology. Palgrave Macmillan, London. https://doi.org/10.1007/978-1-349-10047-7_19
Download citation
DOI: https://doi.org/10.1007/978-1-349-10047-7_19
Publisher Name: Palgrave Macmillan, London
Print ISBN: 978-1-349-10049-1
Online ISBN: 978-1-349-10047-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)